Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis
Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis
复制标题
DOI：
10.5588/ijtld.17.0706
复制
发表时间：
2018-04-01
影响因子：
4
通讯作者：
Furin, J.
中科院分区：
文献类型：
--
作者：
Cox, V;Brigden, G.;Furin, J.
环境：世界卫生组织分别于2013年和2014年推荐了两种新药贝达喹啉（BDQ）和德拉马尼（DLM）用于治疗耐多药结核病（MDR-TB）。估计有三分之一的耐多药结核病患者将从将这些药物纳入其治疗方案中受益。设计：36个国家的便利样本自愿向耐药结核病扩大治疗行动小组报告2015年7月1日至2017年6月31日期间新药累积项目使用的每月数据。程序性使用被定义为治疗耐多药结核病的新药以外的临床试验或同情use.RESULTS：共有10 164人开始对BDQ和688开始对DLM在本报告所述期间。只有15.7%的69 213人估计需要更新的药物在研究期间，据报道已经收到theme.CONCLUSION：虽然有显着的进展，在一些国家，吸收的更新的药物并没有跟上保守估计的需要，不到20%的人可能受益于BDQ或DLM已经收到他们。需要作出协调一致的努力，确保更广泛地向需要这些治疗选择的耐多药结核病患者提供新药。
SETTING: The World Health Organization recommended two new drugs, bedaquiline (BDQ) and delamanid (DLM), for the treatment of multidrug-resistant tuberculosis (MDR-TB) in 2013 and 2014, respectively. An estimated one third of patients with MDR-TB would benefit from the inclusion of these drugs in their treatment regimens.DESIGN: A convenience sample of 36 countries voluntarily reported monthly data on cumulative programmatic use of new drugs to the Drug-Resistant TB ScaleUp Treatment Action Team between 1 July 2015 and 31 June 2017. Programmatic use was defined as treatment for MDR-TB with newer drugs outside of clinical trials or compassionate use.RESULTS: A total of 10 164 persons were started on BDQ and 688 started on DLM during the reporting period. Only 15.7% of the 69 213 persons estimated to need newer drugs over the study period were reported to have received them.CONCLUSION: While there has been significant progress in some countries, uptake of the newer drugs has not kept pace with a conservative estimate of need; fewer than 20% of persons likely to benefit from either BDQ or DLM have received them. Concerted efforts are needed to ensure that the newer drugs are made available more widely for persons with MDR-TB in need of these therapeutic options.